Recent Advancements in the Management of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review

医学 美罗华 显微镜下多血管炎 肉芽肿伴多发性血管炎 血管炎 人口 不利影响 重症监护医学 免疫学 嗜酸性 内科学
作者
Hadia Arzoun,Mirra Srinivasan,Santhosh Raja Thangaraj,Siji S Thomas,Alena Yarema,Bridget Lee,Lubna Mohammed
出处
期刊:Cureus [Cureus, Inc.]
标识
DOI:10.7759/cureus.21814
摘要

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare multisystem autoimmune condition that causes inflammation of small and medium-sized blood vessels and is more commonly seen in the geriatric population. ANCA-associated vasculitis (AAV) is typically characterized as necrotizing vasculitis and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The mortality rate remains high, with especially cardiovascular disease, infections, and malignancies being the leading causes of death. Existing treatment options depend heavily on the use of glucocorticoids (GCs), often in combination with cyclophosphamide (CYC); however, as the multitude of adverse effects associated with these agents has increased, numerous studies are being conducted to reduce not only these harmful effects but also improve remission rates. Rituximab, avacopan, corticosteroids, including intravenous pulse methylprednisolone, plasma exchange, and immunological targeting are among the emerging treatments. The purpose of this review is to emphasize the pathogenesis and traditional treatment modalities and give insights into the recent advances in managing this disorder in an attempt to spare the adverse effects of conventional therapies while achieving better remission rates with combination therapies as well. The authors explored multiple databases, employing appropriate keywords, satisfying the quality appraisal, after which a total of 14 reports were included in this review. Upon overall analysis, it can be concluded that rituximab and CYC, when used in combination, provided a safer alternative to GCs while exhibiting equal, if not superior, effectiveness and results, thus, paving the way for additional in-depth research in a larger population of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
追寻的山晴完成签到,获得积分10
1秒前
852的应助被yy采纳,获得10
1秒前
ppp发布了新的文献求助10
3秒前
胜似闲庭信步完成签到,获得积分10
3秒前
Liii完成签到 ,获得积分10
3秒前
wei发布了新的文献求助10
4秒前
尊敬的驳完成签到,获得积分10
4秒前
JoJo完成签到,获得积分10
6秒前
star完成签到,获得积分10
9秒前
9秒前
小贾完成签到,获得积分10
10秒前
杀死周一完成签到,获得积分10
12秒前
tina酱完成签到 ,获得积分10
14秒前
zhangyiyang完成签到 ,获得积分10
14秒前
隐形骁完成签到,获得积分10
14秒前
15秒前
16601107082发布了新的文献求助10
16秒前
liuchang完成签到 ,获得积分10
16秒前
22336完成签到,获得积分0
16秒前
Lemenchichi完成签到,获得积分10
16秒前
老实的鑫磊完成签到,获得积分20
17秒前
会过期的凤梨完成签到 ,获得积分10
18秒前
hahaha完成签到 ,获得积分10
18秒前
wailwq完成签到 ,获得积分10
19秒前
19秒前
19秒前
怕黑的冰安完成签到,获得积分10
20秒前
大卫戴完成签到 ,获得积分10
20秒前
临天下完成签到,获得积分10
20秒前
小楞楞完成签到,获得积分10
21秒前
tanfor完成签到 ,获得积分10
22秒前
孤星发布了新的文献求助10
22秒前
Matthewwt完成签到,获得积分10
22秒前
hyd完成签到,获得积分10
23秒前
123完成签到,获得积分10
23秒前
大个的应助被16601107082采纳,获得10
24秒前
orixero的应助被仔仔在采纳,获得10
25秒前
123完成签到 ,获得积分10
26秒前
甜美的盼晴完成签到 ,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923